|
|
|
|
|
by lostlogin
1595 days ago
|
|
Maybe the state of play has changed, as we scan for this indication in MR, not PET. Have you a link to something as my understanding is that small lesions are better found with MR? Or is this a rule that applies to high end research work and hasn’t hit clinical practice yet? Maybe a limitation of the isotopes used clinically? |
|
FDG PET/CT is not used to stage intracranial metastases due to background brain activity significantly reducing sensitivity. You’re likely only detecting lesions 1cm or greater in the brain, or ones which demonstrate low metabolic activity and appear dark.
MRI is much more sensitive and specific and is the standard of care for staging in my practice and as per the NCCN clinical guidelines. I haven’t been to any institution or heard of one where PET is used for staging of brain metastases.
Not sure where this is coming from.